UnknownNot Applicable

Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease

Iran80 participantsStarted 2010-10

Plain-language summary

The purpose of this study is to find if Etanercept can improve the outcome of ocular lesions of Behcet's Disease treated with Methotrexate and Prednisolone

Who can participate

Age range16 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Behcet's Disease according to the International Criteria for Behcet's disease (ICBD) * Active posterior uveitis and/or retinal vasculitis Exclusion Criteria: * Visual acuity inferior to 1/10 on Snellen chart * Being under cytotoxic drugs or having received them in the past 2 months * Not being able to follow the one year treatment and the regular follow ups

What they're measuring

Visual Acuity, Disease Activity Index (DAI) for Posterior Uveitis, DAI for Retinal vasculitis

Timeframe: One Year

Trial details

NCT IDNCT00931957

SponsorTehran University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-10

Contact for this trial

Fereydoun Davatchi, MD

(98-21) 8802-6956 fddh@davatchi.net

View on ClinicalTrials.gov More Behcet Syndrome trials